Artiva halts autoimmune cell therapy trial after two patient deaths

Artiva Biotherapeutics is shutting down its autoimmune cell therapy trial following two patient deaths, a setback for the industry's push to apply CAR-T-like strategies to autoimmune diseases. The deaths raise safety concerns that could slow rival programs and dampen investor enthusiasm for the approach. The specific causes of death and whether they are treatment-related remain unconfirmed.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works